These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

867 related articles for article (PubMed ID: 34226483)

  • 21. COVID Associated Mucormycosis: A Study on the Spectrum of Clinical, Biochemical and Radiological Findings in A Series of Ten Patients.
    Pal P; Chatterjee N; Ghosh S; Ray BK; Mukhopadhyay P; Bhunia K; Srivastava SR; Adhikari S; Barman D; Banerjee B; Mukhopadhyay M; Pal J
    J Assoc Physicians India; 2021 Oct; 69(10):11-12. PubMed ID: 34781648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rhino-Orbital Cerebral Mucormycosis in Non-Diabetic Patients with COVID-19.
    Elhamamsy S; Bayer T; Al-Kaffas M; Hatahet S; Grover M; Samdhani S; Nanda A; Gravenstein S
    R I Med J (2013); 2021 Oct; 104(8):19-21. PubMed ID: 34582509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mucormycosis: what emergency physicians need to know?
    Long B; Koyfman A
    Am J Emerg Med; 2015 Dec; 33(12):1823-5. PubMed ID: 26452511
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjunctive use of saturated solution of potassium iodide (SSKI) with liposomal amphotericin B (L-AMB) in mucormycosis achieves favorable response, shortened dose and duration of amphotericin: A retrospective study from a COVID-19 tertiary care center.
    Mrig S; Sardana K; Arora P; Narula V; Arora S; Kapoor A; Baruah RR; Sen P; Agarwal S; Sachdeva S; Dewan A; Panesar S
    Am J Otolaryngol; 2022; 43(3):103465. PubMed ID: 35429848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries.
    Rudramurthy SM; Hoenigl M; Meis JF; Cornely OA; Muthu V; Gangneux JP; Perfect J; Chakrabarti A;
    Mycoses; 2021 Sep; 64(9):1028-1037. PubMed ID: 34133816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rhino-orbito-cerebral mucormycosis during the COVID-19 third wave in 2021: an Egyptian preliminary report from a single tertiary hospital.
    Alloush TK; Mansour O; Alloush AT; Roushdy T; Hamid E; El-Shamy M; Shokri HM
    Neurol Sci; 2022 Feb; 43(2):799-809. PubMed ID: 34787754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COVID-19-associated mucormycosis: Preliminary report from a tertiary eye care centre.
    Walia S; Bhaisare V; Rawat P; Kori N; Sharma M; Gupta N; Urdhwareshwar S; Thakur S; Arya N
    Indian J Ophthalmol; 2021 Dec; 69(12):3685-3689. PubMed ID: 34827023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical-epidemiological Profile of Coronavirus Disease 19 Associated Mucomycosis (CAM) and Relation with Zinc and Iron Levels.
    Karoli R; Kulshreshtha MR; Gupta N; Singh M; Singh V; Shakya S
    J Assoc Physicians India; 2022 Feb; 70(2):11-12. PubMed ID: 35436818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antifungal Effect of Nanoparticles against COVID-19 Linked Black Fungus: A Perspective on Biomedical Applications.
    Gurunathan S; Lee AR; Kim JH
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293381
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rhino-orbital-cerebral-mucormycosis in COVID-19: A systematic review.
    Bhattacharyya A; Sarma P; Sharma DJ; Das KK; Kaur H; Prajapat M; Kumar S; Bansal S; Prakash A; Avti P; Thota P; Reddy DH; Gautam BS; Medhi B
    Indian J Pharmacol; 2021; 53(4):317-327. PubMed ID: 34414911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors influencing mortality in COVID-19-associated mucormycosis: The international ID-IRI study.
    Sahin M; Yilmaz M; Mert A; Naghili B; Ravanbakhsh F; Varshochi M; Darazam IA; Ebrahimi MJ; Moafi M; Tehrani HA; Mahboob A; Rashid N; Khan EA; Hakamifard A; Eser-Karlidag G; Babamahmoodi A; El-Kholy A; Mosawi SH; Albayrak A; Al Ramahi JW; Addepalli SK; Özer Balin Ş; Khan A; Pandya N; Gurbuz E; Sincan G; Azami H; Dumlu R; Khedr R; Ripon RK; Alkan S; Kose Ş; Ceylan B; Erdem H
    Med Mycol; 2024 Jul; 62(7):. PubMed ID: 38914466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Post-Covid Cerebral Mucormycosis, Varied Presentations and Surgical Strategies of a Newer Epidemic: An Institutional Experience.
    Vijayasekhar MV; Nagappa V; Swaroop KH; Mithun G; Achuith E; Varaprasad KS
    Neurol India; 2022; 70(3):1052-1056. PubMed ID: 35864638
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mucormycosis: New Developments into a Persistently Devastating Infection.
    Danion F; Aguilar C; Catherinot E; Alanio A; DeWolf S; Lortholary O; Lanternier F
    Semin Respir Crit Care Med; 2015 Oct; 36(5):692-705. PubMed ID: 26398536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rising concerns of Mucormycosis (Zygomycosis) among COVID-19 patients; an analysis and review based on case reports in literature.
    Ramphul K; Verma R; Kumar N; Ramphul Y; Mejias S; Lohana P
    Acta Biomed; 2021 Sep; 92(4):e2021271. PubMed ID: 34487063
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased incidence of rhino-orbital mucormycosis in an educational therapeutic hospital during the COVID-19 pandemic in western Iran: An observational study.
    Avatef Fazeli M; Rezaei L; Javadirad E; Iranfar K; Khosravi A; Amini Saman J; Poursabbagh P; Ghadami MR; Parandin MM; Dehghani A; Ahmadi Jouybari T; Mahdavian B; Eivazi N; Rezaei S; Rezaei A; Emami B; Haqgou M; Bozorgomid A; Sayad B
    Mycoses; 2021 Nov; 64(11):1366-1377. PubMed ID: 34252988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rhino-Orbital Mucormycosis in a COVID-19 Patient: A Dreadful Challenge.
    Dhakal A; Pokharel M; Madhup S; Khadka L; Sapkota B
    Kathmandu Univ Med J (KUMJ); 2022; 20(78):249-251. PubMed ID: 37017177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mucormycosis: a community hospital perspective.
    Harris LF; Hon JK; Schreeder MT
    Ala Med; 1990; 60(1-2):38, 40-1. PubMed ID: 2239627
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options.
    Riley TT; Muzny CA; Swiatlo E; Legendre DP
    Ann Pharmacother; 2016 Sep; 50(9):747-57. PubMed ID: 27307416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diabetes mellitus as the major risk factor for mucormycosis in Mexico: Epidemiology, diagnosis, and outcomes of reported cases.
    Corzo-León DE; Chora-Hernández LD; Rodríguez-Zulueta AP; Walsh TJ
    Med Mycol; 2018 Jan; 56(1):29-43. PubMed ID: 28431008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Whole genome analysis of
    Michael JS; Venkatesan M; Ninan MM; Solaimalai D; Sumanth LJ; Varghese L; Kurien R; Varghese RP; C GPD
    Front Cell Infect Microbiol; 2023; 13():1251456. PubMed ID: 38029246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.